Introduction. The global demographic trend towards the aging of the population forces us to look for new, more effective ways of geroprotection and treatment of chronic diseases that is common for elderly and senile cases. In the process of searching for pharmacological agents that can slow down the development of age-related involution and prolong the period of active longevity, bioactive peptides seem promising. In this regard, the analysis of possible sources and methods for obtaining bioactive peptides seems relevant and practically significant. Research objectives were studying and analysis of the relevant literature data on the sources and methods of bioactive peptides obtaining. Materials and methods. Scientific methods of theoretical research (induction, deduction, analysis, synthesis, etc.) were used. Information about the sources and methods of bioactive peptides obtaining was selected and analyzed. The potential possibilities of this peptides use in geriatric practice were evaluated. The information was searched among the publicly available literature sources that are indexed by the databases of Scopus, Web of Science, MedLine, The Cochrane Library, EMBASE, Global Health, CyberLeninka, and RSCI. Results and their discussion. It has been established that bioactive peptides known to science are a large group of organic compounds, the number of which is about one and a half thousand. It is known that some bioactive peptides have properties that may be useful in geriatric practice. However, the production of bioactive peptides in commercial quantities requires the availability of appropriate raw materials and technologies. Animal and vegetable proteins can be used as raw materials for the industrial production of bioactive peptides. Methods of enzymatic hydrolysis, microbial fermentation, chemical synthesis, as well as recombinant DNA technologies can be used to obtain bioactive peptides. Existing technologies for the production of bioactive peptides allow, if necessary, to produce them in commercial quantities. Taking into account the protein content in waste from the fish processing and meat and dairy industries, as well as the amount of such waste, we can talk about the availability of a raw material base that is necessary for the industrial production of bioactive peptides. Conclusion. Thus, the results of the study indicate on the availability of the raw material base that is necessary for the production of bioactive peptides, and also indicate on the existence of the technologies that is required for this. All this creates prerequisites for the successful organization of industrial production of pharmaceuticals that is based on bioactive peptides and that have geroprotective and other effects that are useful for geriatric practice.